Recorded: 08 May 2008
For a whole genome? I think [there] is a positive result. So what we could do is we could exclude a lot of things. Right, he doesn’t have…you know, he’s not a super dangerous [risk] for anesthesia. There’s a marker for anesthesia. If you have a certain anesthesia drug and you have that variant, you shouldn’t get a certain type of anesthesia. He doesn’t have that. So he’s healthy on that one. On the cardiovascular side I think we’re getting to the point when it is useful. Now it depends on, we need to stratify population. So if somebody is already at a high risk, a genetic profile, even as of today, makes sense.
Martin Reese is the Co-founder, Chief Executive Officer, and Chairman of the Board of Omicia.
Dr. Martin Reese is an internationally recognized expert in medical informatics and bioinformatics with a track record of bringing strong, grounded scientific knowledge to the corporate sector. Prior to founding Omicia, Dr. Reese served as Vice President of Discovery Informatics for ValiGen. He organized the state-of-the-art Genome Annotation Assessment Project and was a member of the Berkeley Drosophila Genome Project. This project provided the essential proof-of-concept platform for Celera's famous shotgun sequencing technology, which is now internationally recognized - as driving a new standard of excellence in sequencing. It was while at the Lawrence Berkeley National Laboratories that Dr. Reese developed gene-finding algorithms for the Human Genome Project. He holds a Masters degree in Medical Informatics from the University of Heidelberg and a Ph.D. in Genetics jointly from the University of California, Berkeley and the University of Hohenheim, Germany.